載入...
Treatment of advanced hepatocellular carcinoma: immunotherapy from checkpoint blockade to potential of cellular treatment
The absence of potent therapeutic option accounts for the dismal prognosis of advanced hepatocellular carcinoma (HCC) with high mortality and recurrence rate. For a decade, sorafenib is the only approved systemic drug in the first-line setting and warrants as the standard-of-care for HCC in the adva...
Na minha lista:
| 發表在: | Transl Gastroenterol Hepatol |
|---|---|
| Main Authors: | , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
AME Publishing Company
2018
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6286919/ https://ncbi.nlm.nih.gov/pubmed/30603725 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/tgh.2018.10.16 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|